Follow a Wire story to keep its companies, topic, and later updates connected.

Get Started Log In Not investment advice. Past performance ≠ future results.

Loading…

AlgoThesisFollow the news. Track the move.

Wire Tape The Angle Story Method Screener Dashboard About RSS

Prices: Databento (EOD) · Filings: SEC EDGAR · Not investment advice. Past performance ≠ future results.Disclaimer Contact

Wire Tape Briefing Dashboard

Stocks›Healthcare›NMRA

NMRA

Name: AlgoThesis
Author: algothesis

NEUMORA THERAPEUTICS, INC.

NasdaqResearch view

Healthcare · Biological Products, (No Diagnostic Substances)

OverviewFundamentals News Latest filings ↗

Price history

Interactive · live data via TradingView

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR

SectorHealthcare

Income—

Sales—

Book/sh—

Cash/sh—

Dividend TTM—

Payout—

Employees—

IPO—

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

Revenue history unavailable.

N

Follow the news. Follow the move.

NMRA story timeline

Company updates and connected market context, with the dated price move attached.

1

Stories

1

Direct

NMRA direct/Earnings

Jun 17

Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data

Neumora Therapeutics (NMRA) is approaching a binary catalyst as upcoming Phase 3 data for navacaprant, its kappa-opioid receptor antagonist for major depressive disorder, will determine the drug's viability. The readout is a classic high-risk binary event: a hit could re-rate the stock sharply higher, while a miss on a drug that is the company's lead asset would be deeply damaging.

COMMUNITY · $NMRA0 theses

POST YOUR TAKE →

Related Stocks

Loading peers…

Build basket with NMRA Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.

NMRA on the Wire

Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression DataYahoo Finance · Wed · 11:17

Latest on the Wire

Bond Yields Jump and Stocks Slip as Iran Stalemate Unsettles InvestorsNYT Business · 31 min ago OpenAI trails Anthropic as losses deepen and Altman pauses frontier AI trainingCoinDesk · 41 min ago 6% Treasury yields are the biggest risk facing stocks right now. Here’s why.

NMRA NEUMORA THERAPEUTICS, INC. Stock — fundamentals, financials & AI research · AlgoThesis

Quick Ratio—

Current Ratio—

Debt/Eq—

EPS (ttm)—

EPS this Y—

EPS past 3/5Y—

Sales past 3/5Y—

EPS Y/Y TTM—

Sales Y/Y TTM—

Shs Outstand—

ROA—

ROE—

ROIC—

Gross Margin—

Oper. Margin—

Profit Margin—

Since story

+7.2%

2026-06-17 → 2026-08-18

Yahoo Finance · 62d ago

View both sides →

Price change begins at the first available close after publication. It describes what followed; it does not claim the story caused the move.

MarketWatch · 1h ago

Jump in energy bills drives UK inflation to highest rate for four monthsBBC Business · 3h ago

RBA’s Hauser warns of rate hike if inflation risks crystallizeInvesting.com · 4h ago

The Wire scans sources on a rolling cadence — new stories land through the day.